NCT06132256
Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Syndax Pharmaceuticals·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Idiopathic Pulmonary Fibrosis
- Drug/Device/Intervention
- Axatilimab
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Syndax Pharmaceuticals
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Nov 01, 2023
- End date
- Jun 01, 2025
- Enrollment
- 135 participants
Primary outcome
Annualized rate of decline in morning pre-dose trough forced vital capacity (FVC) (milliliter [mL])
Summary
The study will evaluate the efficacy and safety of axatilimab in participants with IPF.
ICD-10 classifications
Other interstitial pulmonary diseases with fibrosisCystic fibrosis with pulmonary manifestationsCystic fibrosisGraphite fibrosis (of lung)Pulmonary heart disease, unspecified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06132256
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06132256 through Pure Global AI's free database. This Phase 2 trial is sponsored by Syndax Pharmaceuticals and is currently Not yet recruiting. The study focuses on Idiopathic Pulmonary Fibrosis. Target enrollment is 135 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.